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The purpose of the present study was to examine the validity and reliability of the handheld Nova Max Plus 
blood glucose monitor during an oral glucose tolerance test and 60-minute bout of exercise. Thirty subjects 
(mean age±SD=22.3±1.9 years; body mass=77.6±14.2 kg) volunteered for an oral glucose tolerance test or a 
60-minute treadmill test. Blood glucose concentrations were measured from the fingertip at six time points 
during both tests. The reference method of blood glucose analysis was the Yellow Springs Instruments (YSI) 
2300. Our results indicated that the blood glucose values provided by the Nova Max Plus were significantly 
(p<.05) greater than the YSI 2300 at all-time points of the oral glucose tolerance test and treadmill test. In 
addition, the Nova Max Plus exhibited an overall mean absolute relative deviation (±SD) of 9.0 (±7.0) and 
did not meet the 95% accuracy requirements of ISO 15197:2013. The Bland-Altman plot for constant error 
(YSI 2300 – Nova Max Plus) versus the reference method (YSI 2300) indicated an average negative bias 
(-8.2 mg·dL-1) that increased (r=-0.23) at higher blood glucose values. Intra-device reliability analyses for 
the Nova Max Plus demonstrated the ICC was R=0.99 and CV=3.0%, with no mean differences between 
the test and retest values. These findings suggested that the Nova Max Plus provided highly reliable, yet 
inaccurate blood glucose values compared to the YSI 2300 during the dynamic conditions associated with 
an oral glucose tolerance test and exercise.
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Introduction
Blood glucose is an important physiological 
variable in clinical settings and human perfor-
mance laboratories due to its relationship with 
various medical conditions and as an indicator of 
energy availability to metabolically active tissue. 
For example, the measurement of blood glucose 
following an overnight fast and oral glucose toler-
ance test (OGTT) are commonly used as screening 
and diagnostic techniques for diabetes mellitus 
(American Diabetes Association, 2018). Specif-
ically, fasting blood glucose values of 100-125 
mg·dL-1 are considered “prediabetic”, whereas 
values >125 mg·dL-1 are classified as “diabetic” 
(American Diabetes Association, 2018). During 
the OGTT procedure, blood glucose levels at 
the two-hour time point of 140-199 mg·dL-1 and 
≥200 mg·dL-1 are classified as “prediabetic” and 
“diabetic”, respectively (American Diabetes Asso-
ciation, 2018). Glucose levels in the blood can also 
be monitored during longer bouts of exercise to 
provide information related to carbohydrate metab-
olism and as a preventative measure against low 
blood sugar (i.e. hypoglycemia). The maintenance 
of adequate blood glucose is vital for proper func-
tioning of various metabolic processes and reflects 
the balance of carbohydrate intake, cellular uptake, 
and glucose release by the liver (Coggan, 1997; Suh, 
et al., 2007). Although exercise provides dynamic 
conditions in which glucose uptake by active skel-
etal muscles increases, this is balanced by glucose 
release from the liver, thereby maintaining nearly 
constant blood glucose values that usually change by 
less than 5-10 mg∙dL-1 (Suh, Paik, & Jacobs, 2007; 
Zinker, Britz, & Brooks, 1990). In addition, the use 
of physical activity as a powerful preventative and 
therapeutic agent against glucose-related disor-
ders has been well-documented (Jelleyman, et al., 
2017). Among other benefits, physical activity stim-
ulates the cellular uptake of glucose independent 
of insulin, promotes insulin sensitivity, weight 
loss, and favorable blood glucose levels (Boulé, 
Kenny, Haddad, Wells, & Sigal, 2003; Boulé, et 
al., 2005; Jelleyman, et al., 2017). Hypoglycemia, 
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or low blood sugar, is a state in which the energy 
demands of the body may not be supplied, thereby 
leading to fatigue, decrements in mental acuity, 
and unconsciousness in extreme cases (American 
Diabetes Association, 2018; Cryer, 2007). The risk 
of hypoglycemia is obviously of greatest concern 
to diabetics, but can also play a factor in athletic 
performance during intense or extensive exercise 
and be indicative of fatigue-inducing glycogen 
depletion (Cermak & van Loon, 2013). Thus, the 
measurement of blood glucose is critical for the 
health, safety, and physical performance of both the 
clinical and athletic individuals in home-, clinical-, 
or laboratory-based environments.
The reference techniques for measuring blood 
glucose typically involve using enzymatic assays 
or isotope dilution gas chromatography-mass spec-
trometry (Hagvik, 2007). For example, the YSI 
2300 STAT PLUS (Yellow Springs Instruments, 
Ohio) analyzes blood glucose using the glucose 
oxidase method and is considered the reference 
method by the U.S. Food and Drug Administra-
tion that most other glucose meters are calibrated 
against (Ekhlaspour, et al., 2017). Although the 
YSI 2300 STAT PLUS offers a high level of preci-
sion (±2% of the reading or 2.5 mg·dL-1) (YSI Life 
Sciences, 2009), it requires expensive and time-
consuming operation and maintenance procedures 
that are only realistic in laboratory and clinical 
settings with trained personnel. In addition, the 
YSI 2300 is designed to be stationary and requires 
an external energy source. Thus, for quick and 
easy blood glucose measurement in the field (e.g. 
health fairs, schools, exercise facilities), or as a 
point-of-care test at home, the portable handheld 
glucose monitors provide an attractive alternate 
over the more complex, laboratory-based proce-
dures. These portable handheld glucose monitors 
are considered highly user-friendly (e.g. simple to 
operate, small size, battery-powered), cost effec-
tive, and can produce results in approximately five 
seconds from less than a drop of blood (i.e. 0.3 µL). 
Although measures of quality control have been 
assessed in many handheld glucose monitors in 
the fasted state (Robinson & Sharp, 2012; Tack, et 
al., 2012; Thomas, et al., 2008) or in vitro (Bedini, 
Wallace, Pardo, & Petruschke, 2015; Ekhlaspour, 
et al., 2017), there are limited data regarding these 
factors in vivo under dynamic conditions of blood 
glucose. Therefore, the purpose of the present study 
was to examine the validity and reliability of the 
handheld Nova Max Plus (Nova Biomedical Corp., 
Waltham, MA) blood glucose monitor during an 
OGTT and 60-minute bout of exercise.
Methods
Subjects
A total of 30 subjects (mean age±SD=22.3±1.9 
years; body mass=77.6±14.2 kg; body height= 
171.3±9.6 cm; physical activity=6.2±4.3 hr·wk-1) 
were recruited from undergraduate courses in 
kinesiology and physical education to participate 
in a single visit to the Human Performance Labo-
ratory for an OGTT (n=15) or a 60-minute tread-
mill exercise test (n=15). The subjects did not report 
or exhibit any of the following that could signifi-
cantly affect the outcome of the study: (i) history 
of medical or surgical events, including cardiovas-
cular disease, heart disease, hypertension, diabetes 
mellitus, insulin resistance, hypoglycemia, or any 
other metabolic, renal, hepatic, or musculoskeletal 
disorder; (ii) phobia to needles or finger-stick; (iii) 
fasting blood glucose level >100 mg·dL-1, or (iv) any 
current physical injury due to the physical demands 
and requirements of the study. Subjects recruited 
for the OGTT (n=15) were asked to avoid eating or 
drinking anything other than water for eight hours 
prior to their visit, whereas the subjects recruited 
to participate in the 60-minute treadmill exer-
cise (n=15) were asked to avoid eating or drinking 
anything other than water for 2-3 hours prior to their 
visit. The study was approved by the Institutional 
Review Board at Northern Illinois University, and 
all participants completed a health history question-
naire and signed a written informed consent docu-
ment prior to testing.
Oral Glucose Tolerance Test (OGTT)
Fifteen subjects (mean age±SD=22.4±1.7 years; 
body mass=77.0±13.2 kg; body height=170.5±10.6 
cm; physical activity=5.0±2.5 hr·wk-1) were tested 
in the morning following an 8-hour overnight fast. 
Subjects had a baseline (0 min) blood glucose meas-
urement taken immediately prior to the ingestion 
of the glucose drink to ensure the subjects were in 
a fasted state with normal levels of blood glucose 
(<100 mg·dL-1). If blood glucose levels were within 
normal range, the subjects were asked to ingest a 
drink (296 mL) that consisted of 75 grams of glucose 
(ThermoFisher Scientific, Waltham, MA). Subjects 
were then asked to sit quietly in the laboratory with 
their blood glucose being measured at the 10-, 20-, 
30-, 60-, and 90-minute time points of the OGTT. 
Treadmill exercise
Fifteen subjects (mean age±SD=22.3±2.2 years; 
body mass=78.2±15.6 kg; body height=172.2±8.7 
cm; physical activity=7.3±5.4 hr·wk-1) were tested 
for their blood glucose responses during 60 minutes 
of walking on a treadmill (Woodway Desmo HP, 
Waukesha, WI). Subjects had a baseline (0 min) 
blood glucose measurement taken immediately 
prior to the treadmill test in which they were asked 
to walk at 5.6 km·hr-1 for a total of 60 minutes. 
This velocity was selected to exceed the minimum 
walking velocity (4.8 km·hr-1) recommended for 
health benefits (Kelly, Murphy, Oja, Murtagh, & 
Foster, 2011). Blood glucose was measured at the 
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5-, 10-, 15-, 30-, and 60-minute time points of the 
test. At each of these time points, the treadmill belt 
was briefly paused to safely allow for the measure-
ment of blood glucose with the subject standing 
still. Following each measurement, the subject was 
instructed to continue the test at 5.6 km·hr-1 until the 
60-minute time point had been reached.
Measurement of blood glucose 
Blood glucose concentrations were measured 
from the fingertip at six different time points during 
the OGTT (0, 10, 20, 30, 60, and 90 min) and tread-
mill test (0, 5, 10, 15, 30, and 60 min). Following 
the standard procedure, the finger was cleaned with 
alcohol before the initial finger prick and prior to 
each blood sample. In addition, the initial blood 
drop that formed on the finger was wiped away and 
the subsequent blood drops were sampled for anal-
ysis and used as the representative blood glucose 
concentrations. During the OGTTs and treadmill 
tests, one blood sample was analyzed four times at 
each time point, two by the YSI 2300 and two by the 
handheld device (Nova Max Plus, Nova Biomedical 
Corp., Waltham, MA). Specifically, 50 µL of whole 
capillary blood was collected at each time point 
using two heparinized capillary tubes and trans-
ferred into a 1.5 mL graduated natural micro-centri-
fuge tube. This sample was analyzed twice by the 
YSI 2300 and twice by the Nova Max Plus using a 
micropipette to present the sample to the glucose 
monitor. The criterion reference method of blood 
glucose analysis used in the present study was the 
Yellow Springs Instruments (YSI) 2300 Stat Plus 
Glucose and Lactate analyzer (Yellow Springs, 
OH). The YSI 2300 measures blood glucose from 
whole blood using the glucose oxidase method. 
This technique required two, 25 µL of whole blood 
collected into heparinized capillary tubes from a 
finger-stick. Duplicate YSI blood glucose results 
were required to be within ±4 mg·dL-1 to be used 
for analysis and the average of these two meas-
urements was used as the representative YSI 2300 
value. The YSI 2300 whole blood glucose values 
were then converted to plasma equivalents (whole 
blood * 1.12 = plasma), and this value was compared 
with the test strip results of the handheld device 
(Nova Max Plus). For quality control, the YSI 2300 
was calibrated against 180 and 900 mg·dL-1 solu-
tions according to the manufacturer guidelines (YSI 
Life Sciences, 2009). The handheld device required 
0.3 µL of whole blood for the measurement of blood 
glucose within 20-600 mg·dL-1 using an electro-
chemical glucose oxidase biosensor. In addition, the 
handheld device was checked for accuracy against 
a known quality control solution prior to testing as 
recommended by the manufacturer (Nova Biomed-
ical Corp.). 
Data analysis
Data were analyzed using SPSS version 24.0 
(SPSS Inc. Armonk, NY: IBM Corp.) and provided 
as mean±SD. Accuracy of the handheld glucose 
monitor compared to the reference YSI 2300 values 
involved multiple analyses. First, mean differences 
in blood glucose values between the YSI 2300 and 
handheld monitor across time during the OGTT 
and exercise tests were assessed using separate 
two-way (method x time) analyses of variance 
(ANOVAs) with repeated measures and follow-
up paired-samples t-tests when appropriate. Accu-
racy was also assessed through: 1) the calculation 
of the mean absolute relative difference (MARD); 
2) comparing test results of the handheld monitor 
against the International Organization for Standard-
ization performance standards (ISO 15197:2013); 
and 3) Bland-Altman (1986) plots with associated 
calculation of constant error (CE = mean difference 
for YSI blood glucose – handheld blood glucose) 
and Pearson correlation coefficient (r). The MARD 
was calculated as the mean of individual absolute 
relative difference (ARD) values. Each individual 
ARD was calculated as:
ARD = 100
(Nova Max value-YSI 2300 value)
YSI 2300 value
Intra-device reliability for the handheld glucose 
meter was assessed using coefficient of variation 
(CV), intra-class correlation coefficient (ICC), and 
paired-samples t-tests. A p-value of 0.05 was used 
for statistical significance.
Results
Accuracy. The results of the two-way repeated 
measures ANOVA for blood glucose values during 
the OGTT indicated there was a significant (p<.05) 
method x time interaction [F(5,70)=2.806, p=.023]. 
Follow-up paired-samples t-tests indicated that the 
handheld monitor resulted in significantly greater 
blood glucose values than the YSI 2300 at all time 
points (Table 1). For blood glucose values during 
the treadmill exercise test, there was no significant 
method x time interaction [F(5,70)=0.868, p=.507] 
or main effect for time [F(5,70)=0.533, p=.751], but 
there was a main effect for method [F(1,14)=12.191, 
p=.004]. A follow-up paired samples t-test indi-
cated that the handheld monitor (86.2±18.8 mg·dL-1) 
resulted in significantly greater blood glucose values 
than the YSI 2300 (81.3±19.8 mg·dL-1) (collapsed 
across time) (Table 1). The MARD (±SD) and accu-
racy values for the Nova Max Plus compared to the 
reference YSI 2300 method are provided in Table 2. 
Specifically, the overall MARD±SD was 9.0±7.0% 
and the combined blood glucose values (OGTT and 
treadmill exercise tests, n=180) that were within the 
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Table 1. Mean±SD blood glucose values from the YSI 2300 and Nova Max Plus during an oral glucose tolerance test and treadmill 
exercise
Oral glucose tolerance test time (minutes) (n=15)
Method  0  10  20  30  60  90
YSI 2300 (mg·dL-1)  87.3±4.7  116.0±10.4  143.4±13.5  158.5±16.6  132.7±21.8  113.5±12.7
Nova Max Plus (mg·dL-1)   97.3±8.0*   130.9±12.6*   157.7±17.4*   170.9±19.7*   141.5±22.3*   120.2±15.2*
Treadmill exercise time (minutes) (n=15)
Method  0  5  10  15  30  60
YSI 2300 (mg·dL-1)  86.1±9.9  84.6±9.5  85.9±8.2  85.3±7.2  86.1±5.4  87.6±6.0
Nova Max Plus (mg·dL-1)†  91.8±9.2  90.6±8.1  89.9±8.0  90.7±8.5  92.4±8.0  90.7±7.5
Note. *Significantly (p<.05) greater than YSI 2300 blood glucose value. †Main effect (p<.05) for method (Nova Max Plus > YSI 2300) 
collapsed across time.
 Figure 1. The relationship between constant error (YSI 2300 
– Nova Max Plus) and the YSI 2300 blood glucose reference 
values (n = 180; 30 subjects x 6 time points = 180). A dashed 
line represents the regression line.
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Figure 2. Test-retest reliability for the Nova Max Plus (n = 
180; 30 subjects x 6 time points= 180).
ISO 15197:2013 criteria was 87.2% (157/180) (Table 
2). The Bland-Altman plot indicated there was a 
signifi cant (p<.05) negative relationship (r=-0.23) 
for CE (YSI 2300 – Nova Max Plus) versus the 
reference method (YSI 2300) as well as a negative 
bias (CE=-8.15 mg·dL-1) (Figure 1).
Reliability. The test-retest intra-device reli-
ability analyses for the Nova Max Plus during the 
OGTT and treadmill exercise test indicated there 
was no signifi cant (p>.05) mean difference between 
measurement 1 (113.9±31.2 mg·dL-1) and measure-
ment 2 (113.6±31.4 mg·dL-1) on the combined data 
(n=180). The ICC and CV associated with meas-
urement 1 versus measurement 2 were R=0.99 and 
3.0%, respectively. In addition, the relationship 
between measurement 1 and measurement 2 from 
the Nova Max Plus resulted in a signifi cant corre-
lation (r=0.99) (Figure 2).
Discussion and conclusions
This study examined the validity and reliability 
of the handheld Nova Max Plus (Nova Biomedical 
Corp., Waltham, MA) blood glucose monitor during 
an OGTT and 60-minute bout of exercise. The blood 
glucose responses during the OGTT and 60 minutes 
of treadmill exercise (Table 1) were comparable to 
those previously reported for healthy individuals 
(Liu, et al. 2008; Zinker, et al. 1990). Specifi cally, 
the blood glucose values (mean±SD) during the 
75-g OGTT at the 0-min (87.3±4.7 mg·dL-1) and 
90-min (113.5±12.7 mg·dL-1) time points were below 
those associated with prediabetes (fasting: 100-125 
mg·dL-1; 120-min: 140-199 mg·dL-1) and diabetes 
(fasting: >125 mg·dL-1; 120-min: >200 mg·dL-1) 
(American Diabetes Association, 2018). In addi-
tion, the range in blood glucose values (84.6±9.5 
to 87.6±6.0 mg·dL-1) during the treadmill test were 
similar to those reported by Zinker et al. (1990) over 
60 minutes of moderate intensity exercise. Thus, 
the subjects in the present study exhibited blood 
glucose responses during the OGTT and 60-min 
exercise test that were consistent with healthy, non-
diabetic individuals of comparable age (Liu, et al., 
2008; Zinker, et al., 1990).
Accuracy. One of the main fi ndings of the 
present study was that the Nova Max Plus provided 
signifi cantly greater blood glucose values than the 
reference method (YSI 2300) under both condi-
tions at all time points of the tests (Table 1). There-
fore, the Nova Max Plus consistently overestimated 
blood glucose provided by the YSI 2300. In addi-
tion, the MARD and ISO 15197:2013 requirements 
were used to examine the accuracy of the hand-
held monitor within different reference ranges 
of blood glucose. Specifi cally, the calculation of 
MARD provides the mean absolute difference 
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value between the Nova Max Plus and reference 
method (YSI 2300) expressed as a percent of the 
reference value (Obermaier, et al. 2013). Thus, the 
MARD describes the magnitude of percentage bias 
of each measurement (Tack, et al. 2012) and a lower 
MARD value is associated with higher accuracy 
(i.e. closer to the reference value). Although there 
are no set criteria for an “accurate” versus “inac-
curate” MARD, values ranging from 4.2 to 39.2 
have been reported for multiple handheld units 
(Ekhlaspour, et al. 2017; Robinson & Sharp, 2012; 
Tack, et al. 2012). Our results indicated that the 
Nova Max Plus exhibited an overall MARD (±SD) 
of 9.0 (±7.0) (n=180), and values of 9.0 (±7.3) and 
9.1 (±6.6) at the low (<100 mg·dL-1, n = 105) and 
high (>100 mg·dL-1, n = 75) reference ranges of 
blood glucose, respectively (Table 2). The overall 
MARD value of 9.0 was consistent with previous 
findings for the Nova Max Plus under fasting condi-
tions (MARD = 8.1) (Robinson & Sharp, 2012) and 
in vitro preparations (MARD = 9.7) (Ekhlaspour, 
et al. 2017) that involved blood samples modified 
for glucose (20-440 mg·dL-1). In addition, Ekhla-
spour et al. (2017) reported overall MARD (±SD) 
values ranging from 5.6 (±6.4) to 20.8 (±16.6) for 17 
different handheld blood glucose monitors versus 
the YSI 2300, with the Nova Max Plus ranking 8th 
for the lowest MARD (9.7). Therefore, the findings 
of the present study and those of others (Ekhlaspour, 
et al. 2017; Robinson & Sharp, 2012) indicated that 
Nova Max Plus provides consistent MARD values 
(9.0-9.7) within a wide range of blood glucose 
during fasting and dynamic conditions.
Although the present study was not conducted 
in vitro according to the strict compliance guide-
lines of ISO 15197:2013 that require the manipula-
tion of blood glucose and hematocrit, their accuracy 
criteria was utilized in the evaluation of validity. 
The ISO 15197:2013 accuracy requirements for 
blood glucose monitoring systems specify that 95% 
of the measured values be within ±15 mg∙dL-1 of the 
reference for values <100 mg∙dL-1 and within ±15% 
for values >100 mg∙dL-1 (ISO 15197:2013). Overall, 
the Nova Max Plus did not meet the 95% accuracy 
criteria, yielding only 87.2% of readings within the 
required range (Table 2). To further examine the 
accuracy of the Nova Max Plus, we determined the 
percentage of readings that fell within the required 
range for values above and below 100 mg∙dL-1. In 
the reference range <100 mg∙dL-1, the Nova Max 
Plus was only within ±15 mg∙dL-1 for 87.6% (92/105) 
of the values. For the reference range >100 mg∙dL-1, 
only 86.7% (65/75) of the values were within the 
ISO 15197:2013 requirements of ±15%. The results 
of these analyses indicated that the Nova Max Plus 
did not meet the ISO requirements in any of the 
three ranges (high, low, overall) of blood glucose 
that we examined. These findings are consistent 
with previous studies that have examined Nova 
Max Plus within fasting individuals and in vitro 
(Ekhlaspour, et al., 2017; Robinson & Sharp, 2012) 
in which the Nova Max was found to have overall 
ISO 15197:2013 accuracy values of 89.0% and 
88.2%, respectively.
The relationship between CE (YSI 2300 – Nova 
Max Plus) and the reference (YSI 2300) blood 
glucose values was analyzed using the method of 
Bland and Altman (1986) (Figure 1). For this rela-
tionship, the mean CE was -8.15 mg·dL-1 and corre-
lation coefficient was r=-0.23. Constant error (CE) 
provides the mean difference between the actual 
(YSI 2300) and predicted (Nova Max Plus) blood 
glucose values. Specifically, the negative CE of 
-8.15 mg·dL-1 indicated that, on average, the Nova 
Max Plus overestimated the measurement of blood 
glucose by 8.15 mg·dL-1. In fact, 81% (145/180) of the 
blood glucose measurements from the Nova Max 
Plus resulted in overestimated values. The negative 
correlation (r=-0.23) suggested that the absolute CE 
values became greater at the high end of the refer-
ence (YSI 2300) blood glucose values. Thus, the 
Nova Max Plus overestimated blood glucose values 
by approximately 8.15 mg·dL-1 and this error tended 
to increase at higher blood glucose values.
Reliability. The intra-device test-retest relia-
bility analyses of the Nova Max Plus were performed 
Table 2. Accuracy of Nova Max Plus in different reference blood glucose ranges
 Overall  <100 mg∙dL-1  >100 mg∙dL-1
MARD±SD (%) 9.0±7.0  9.0±7.3  9.1±6.6
95% CI 8.0 to 10.1  7.6 to 10.4  7.6 to 10.6
Values within         
±5%/5 mg∙dL-1 80/180 (44.4%)  53/105 (51.5%)  27/75 (36.0%)
±10%/10 mg∙dL-1 149/180 (82.8%)  76/105 (72.4%)  43/75 (57.3%)
±15%/15 mg∙dL-1 157/180 (87.2%)  92/105 (87.6%)  65/75 (86.7%)
ISO standards* met? No  No  No
Note. *ISO 15197:2013 standards require that 95% of values <100 mg∙dL-1 be within ±15 mg∙dL-1 of reference value and 95% of values 
>100 mg∙dL-1 be within ±15%.
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on the two blood glucose measurements taken at 
each time point during the OGTT and treadmill test 
(30 subjects x 6 time points = 180 comparisons). 
As recommended by Atkinson and Nevill (1998), a 
number of statistical methods should be utilized for 
assessing reliability in variables relevant to sports 
medicine to provide a comprehensive analysis. Our 
findings indicated there were no significant mean 
differences between the first (113.9±31.2 mg·dL-1) 
and second (113.6±31.4 mg·dL-1) measurements. 
Although suitable, the t-statistics does not provide 
an indication of random variation between tests 
and should be interpreted with caution (Atkinson 
& Nevill, 1998). Thus, we also utilized the ICC and 
CV as two additional statistical procedures that are 
commonly used to assess relative and absolute reli-
ability, respectively (McLain, et al., 2015). The ICC 
is used to describe the strength of the similarity of 
the values within a group and categories suggested 
by Vincent and Weir (2012) include “excellent” 
(R close to 1), “high” (R>0.90), “good” (R=0.80-
0.89), and “questionable” (R=0.70-0.79). For CV, 
an acceptable boundary of <10% has been previ-
ously proposed (Atkinson & Nevill, 1998; McLain, 
et al. 2015). Therefore, the Nova Max Plus exhib-
ited excellent relative reliability (ICC, R=0.99) and 
acceptable absolute reliability (CV=3.0%). Collec-
tively, these analyses indicated that the Nova Max 
Plus provided highly reliable blood glucose values 
on two consecutive measurements taken at the same 
time points during the OGTT and treadmill test.
Implications and limitations. The present 
study provides meaningful data for health care 
providers, clinicians, coaches and trainers in human 
performance, and other fitness professionals for 
assessing blood glucose in the field or laboratory 
during exercise, fasting, or postprandial. Overall, 
our findings suggested that readings from the Nova 
Max Plus for the screening or diagnosis of blood 
glucose-related disorders at health fairs, schools, 
in the laboratory, etc., should be interpreted with 
caution. These findings should also be taken into 
consideration for individuals that require accurate 
blood glucose readings that determine the appro-
priateness for exercise, food ingestion, or insulin 
injections. It should be noted, however, that this 
study was not without limitations. Specifically, our 
sample only included healthy subjects without any 
glucose-related disorders. It is likely that many indi-
viduals that use Nova Max Plus handheld glucose 
monitors suffer from insulin resistance, diabetes, 
or other metabolic problems. In addition, the blood 
glucose responses to the OGTT in our sample of 
healthy individuals did not exceed 200 mg·dL-1. 
Therefore, the validity and reliability of the Nova 
Max Plus were not assessed using a blood glucose 
range (i.e. >200 mg·dL-1) consistent with impaired 
glucose homeostasis. Importantly, however, our 
findings indicated that higher blood glucose values 
were associated with less accurate readings from 
the Nova Max Plus. Future studies should consider 
examining the accuracy and reliability of the Nova 
Max Plus and other handheld blood glucose moni-
tors during more intense and longer duration bouts 
of exercise that may be associated with hypogly-
cemia or glycogen depletion in athletes, or during 
dynamic conditions in clinical populations (i.e. 
Type 1 and 2 diabetes) that exhibit large ranges in 
blood glucose responses.
In summary, the blood glucose values provided 
by the handheld Nova Max Plus were significantly 
higher than those of the YSI 2300 reference method 
at all time points of the OGTT and 60-minute tread-
mill test. In addition, the Nova Max Plus exhib-
ited an overall MARD (±SD) of 9.0 (±7.0) and 
failed to meet the 95% accuracy requirements of 
ISO 15197:2013 (only 87.2% of all values met the 
criteria). The Bland-Altman plot for CE (YSI 2300 
– Nova Max Plus) versus the reference method (YSI 
2300) indicated an average negative bias (CE=-8.2 
mg·dL-1) that tended to increase (r=-0.23) at higher 
blood glucose values. The intra-device reliability 
analyses of the Nova Max Plus, however, demon-
strated that the ICC was R=0.99 and CV=3.0%, with 
no significant mean differences between the test 
and retest values. These findings suggested that the 
Nova Max Plus provided highly reliable, yet inac-
curate blood glucose values compared to the YSI 
2300 during the dynamic conditions associated with 
an OGTT and exercise. 
References 
American Diabetes Association. (2018). 2. Classification and diagnosis of diabetes: Standards of medical care in 
diabetes-2018. Diabetes Care, 41(Supplement 1), S13-S27. doi: 10.2337/dc18-S002
Atkinson, G., & Nevill, A.M. (1998) Statistical methods for assessing measurement error (reliability) in variables 
relevant to sports medicine. Sports Medicine, 26(4), 217-238.
Bedini, J.L., Wallace, J.F., Pardo, S., & Petruschke, T. (2015). Performance evaluation of three blood glucose monitoring 
systems using ISO 15197: 2013 accuracy criteria, consensus and surveillance error grid analyses, and insulin 
dosing error modeling in a hospital setting. Journal of Diabetes Science and Technology, 10(1), 85-92. doi: 
10.1177/1932296815609368 
Bland, J.M., & Altman, D.G. (1986). Statistical methods for assessing agreement between two methods of clinical 
measurement. The Lancet, 327(8476), 307-310.
Kinesiology 51(2019)2:182-188Granderson, D.M. et al.: VALIDITY AND RELIABILITY OF A HANDHELD BLOOD...
188
Boulé, N.G., Kenny, G.P., Haddad, E., Wells, G.A., & Sigal, R.J. (2003). Meta-analysis of the effect of structured 
exercise training on cardiorespiratory fitness in Type 2 diabetes mellitus. Diabetologia, 46(8), 1071-1081. doi: 
10.1007/s00125-003-1160-2
Boulé, N.G., Weisnagel, S.J., Lakka, T.A., Tremblay, A., Bergman, R.N., Rankinen, T., et al. (2005). Effects of exercise 
training on glucose homeostasis: The HERITAGE family study. Diabetes Care, 28(1), 108-114. 
Cermak, N.M., & van Loon, L.J. (2013). The use of carbohydrates during exercise as an ergogenic aid. Sports Medicine, 
43(11), 1139-1155. doi: 10.1007/s40279-013-0079-0
Coggan, A.R. (1997). Plasma glucose metabolism during exercise: Effect of endurance training in humans. Medicine 
and Science in Sports and Exercise, 29(5), 620-627.
Cryer, P.E. (2007). Hypoglycemia, functional brain failure, and brain death. The Journal of Clinical Investigation, 
117(4), 868-870. doi: 10.1172/JCI31669
Ekhlaspour, L., Mondesir, D., Lautsch, N., Balliro, C., Hillard, M., Magyar, K., et al. (2017). Comparative accuracy of 17 
point-of-care glucose meters. Journal of Diabetes and Technology, 11(3), 558-566. doi: 10.1177/1932296816672237
Hagvik, J. (2007). Glucose measurement: Time for a gold standard. Journal of Diabetes Science and Technology, 1(2), 
169-172. doi: 10.1177/193229680700100205
International Organization for Standardization. (2013). ISO 15197:2013: In vitro diagnostic test systems – Requirements 
for blood-glucose monitoring systems for self-testing in managing diabetes mellitus. Retrieved January 4, 2018 
from: https://www.glucomen.co.uk/wp-content/themes/glucomen/assets/pdfs/Areo_ISO_Accuracy_bro.pdf 
Jelleyman, C., Edwardson, C.L., Henson, J., Gray, L.J., Rowlands, A.V., Khunti, K., et al. (2017). Associations of 
physical activity intensities with markers of insulin sensitivity. Medicine and Science in Sports and Exercise, 
49(12), 2451-2458. doi: 10.1249/MSS.0000000000001381
Kelly, P., Murphy, M., Oja, P., Murtagh, E.M., & Foster, C. (2011). Estimates of number of people in England who 
attain or exceed vigorous intensity exercise by walking at 3 mph. Journal of Sports Sciences, 29(15), 1629-1634. 
doi: 10.1080/02640414.2011.609897
Liu, T., Liu, Y., Lee, S., Huang, C., Chien, K., Cheng, I., et al. (2008). Effects of short-term detraining on 
measures of obesity and glucose tolerance in elite athletes. Journal of Sports Sciences, 26(9), 919-925. doi: 
10.1080/02640410801885925
McLain, T.A., Wright, G.A., Camic, C.L., Kovacs, A.J., Hegge, J.M., & Brice, G.A. (2015). Development of an anaerobic 
sprint running test using a nonmotorized treadmill. Journal of Strength and Conditioning Research, 29(8), 
2197-2204. doi: 10.1519/JSC.0000000000000854.
Obermaier, K., Schmelzeisen-Redeker, G., Schoemaker, M., Klötzer, H.M., Kirchsteiger, H., Eikmeier, H., et al. (2013). 
Performance evaluations of continuous glucose monitoring systems: Precision absolute relative deviation is part 
of the assessment. Journal of Diabetes Science and Technology, 7(4), 824-832. doi: 10.1177/193229681300700404
Robinson, C.S., & Sharp, P. (2012). Tighter accuracy standards within point-of-care blood glucose monitoring: 
How six commonly used systems compare. Journal of Diabetes Science and Technology, 6(3), 547-554. doi: 
10.1177/193229681200600309
Suh, S., Paik, I., & Jacobs, K.A. (2007). Regulation of blood glucose homeostasis during prolonged exercise. Molecules 
and Cells, 23(3), 272-279. 
Tack, C., Pohlmeier, H., Behnke, T., Schmid, V., Grenningloh, M., Forst, T., et al. (2012). Accuracy evaluation of five 
blood glucose monitoring systems obtained from the pharmacy: A European multicenter study with 453 subjects. 
Diabetes Technology and Therapeutics, 14(4), 330-337. doi: 10.1089/dia.2011.0170 
Thomas, L.E., Kane, M.P., Bakst, G., Busch, R.S., Hamilton, R.A., & Abelseth, J.M. (2008). A glucose meter accuracy 
and precision comparison: The FreeStyle Flash versus the Accu-Check Advantage, Accu-Check Compact Plus, 
Ascenia Contour, and the BD Logic. Diabetes Technology and Therapeutics, 10(2), 102-110. doi: 10.1089/
dia.2007.0244
Vincent, J., & Weir, J.P. (2012). Statistics in kinesiology (4th ed.). Champaign, IL: Human Kinetics.
YSI Life Sciences. (2009). User’s Manual YSI 2300 STAT PLUS Glucose and L-Lactate Analyzer. Retrieved January 4, 
2018 from: https://www.ysi.com/File%20Library/Documents/Manuals%20for%20Discontinued%20Products/
YSI-2300-Stat-Plus-manual-j.pdf
Zinker, B.A., Britz, K., & Brooks, G.A. (1990). Effects of a 36-hour fast on human endurance and substrate utilization. 
Journal of Applied Physiology, 69(5), 1849-1855. doi: 10.1152/jappl.1990.69.5.1849.
Correspondence to:
Assoc. Prof. Clayton L. Camic, Ph.D.
Kinesiology and Physical Education
228 Anderson Hall
Northern Illinois University




Submitted: November 6, 2018
Accepted: January 8, 2019.
Published Online First: November 7, 2019
